TruNature (Resveratrol)

Resveratrol is a polyphenolic stilbenoid found in grapes, berries, and red wine that activates the longevity-associated sirtuin SIRT1 deacetylase enzyme. Its primary mechanisms include AMPK pathway activation, inhibition of NF-κB inflammatory signaling, and modulation of oxidative stress via Nrf2 upregulation.

Origin & History

TruNature Resveratrol is a natural polyphenolic compound primarily sourced from the skin of red grapes (Vitis vinifera), Japanese knotweed (Polygonum cuspidatum), and berries, extracted via solvent methods like ethanol or acetone. It belongs to the stilbenoid chemical class, specifically a phytoalexin produced by plants in response to stress, typically standardized to 98-99% trans-resveratrol purity.

Historical & Cultural Context

Resveratrol from Japanese knotweed has been used in Traditional Chinese Medicine for centuries for cardiovascular health and inflammation. Grape-derived forms connect to Mediterranean dietary traditions for heart health, though purified resveratrol supplements are a modern development.

Health Benefits

• Improves endothelial function - Meta-analysis of 17 studies showed increased flow-mediated dilation by 1.43% (Strong evidence)
• Reduces inflammation markers - Multiple RCTs demonstrated reductions in TNF-alpha, hs-CRP, and ICAM-1 levels (Strong evidence)
• Supports type 2 diabetes management - RCTs with 614+ participants showed improvements in fasting glucose, HbA1c, and insulin levels (Moderate evidence)
• Enhances lipid profiles - Clinical trials reported reduced total cholesterol and triglycerides at 100-500mg daily doses (Moderate evidence)
• Provides antioxidant support - Studies showed increased antioxidant markers including TAS, PTX3, and PON1 (Moderate evidence)

How It Works

Resveratrol binds and activates SIRT1, a NAD+-dependent deacetylase that regulates gene expression linked to metabolic homeostasis, inflammation, and cellular senescence. It simultaneously activates AMP-activated protein kinase (AMPK), improving insulin sensitivity and mitochondrial biogenesis via PGC-1α upregulation. Additionally, resveratrol inhibits NF-κB nuclear translocation, suppressing downstream pro-inflammatory cytokines including TNF-alpha, IL-6, and COX-2-derived prostaglandins.

Scientific Research

A 2025 meta-analysis of 21 arms from 17 RCTs found resveratrol significantly improved endothelial function (FMD increase of 1.43%, p<0.001) and reduced ICAM-1 levels. Key RCTs include Chen 2016 (n=312 stroke patients), Movahed 2013 (n=66 T2D patients), and Simental-Mendia 2019 (n=71 dyslipidemic adults), though specific PMIDs were not provided in the research dossier.

Clinical Summary

A meta-analysis of 17 randomized controlled trials demonstrated that resveratrol supplementation increased flow-mediated dilation by 1.43%, indicating measurable improvement in endothelial function. Multiple RCTs have documented significant reductions in TNF-alpha, hs-CRP, and ICAM-1, supporting an anti-inflammatory effect at doses typically ranging from 150 to 1000 mg per day. Evidence for type 2 diabetes management is encouraging, with several RCTs showing reduced fasting glucose and improved insulin sensitivity, though study populations have been modest in size. Overall, cardiovascular and metabolic evidence is rated strong, while anti-aging and neuroprotective claims require larger long-term human trials.

Nutritional Profile

Primary bioactive compound: trans-Resveratrol (3,5,4'-trihydroxystilbene), typically 250 mg per softgel in TruNature formulations. Often paired with additional polyphenolic support such as red wine extract (providing additional polyphenols including quercetin, catechins, and anthocyanins) and grape seed extract (source of oligomeric proanthocyanidins/OPCs, typically 50–100 mg per serving). Negligible macronutrient content (essentially zero protein, carbohydrate, and fat beyond trace amounts from the softgel carrier oil). No significant vitamins or minerals. The softgel delivery form uses a lipid-based carrier (often soybean or another vegetable oil) which may modestly enhance absorption of the lipophilic resveratrol. Bioavailability notes: Oral trans-resveratrol has low intrinsic bioavailability (~1–5% unchanged in plasma) due to rapid Phase II metabolism in the intestine and liver, producing sulfate and glucuronide conjugates (resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide) which may retain partial biological activity. Peak plasma levels occur approximately 0.5–2.5 hours post-ingestion. Taking with a fat-containing meal may improve absorption. Despite low parent compound bioavailability, metabolites achieve substantially higher circulating concentrations and contribute to observed clinical effects. The typical TruNature product provides 250 mg trans-resveratrol per capsule with a recommended dose of 1 capsule daily, aligning with doses used in clinical trials (150–500 mg/day) that demonstrated cardiovascular, anti-inflammatory, and glycemic benefits.

Preparation & Dosage

Clinical studies used oral doses ranging from 40-500 mg/day in capsule form. For type 2 diabetes: 500 mg once or twice daily for 45 days to 6 months. For dyslipidemia: 100 mg daily for 2 months. Acute IV use in stroke was 2.5 mg/kg. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Curcumin, Green Tea Extract, NAD+ precursors, Omega-3 fatty acids

Safety & Interactions

Resveratrol is generally well tolerated at doses up to 1000 mg per day, with the most commonly reported side effects being gastrointestinal discomfort including nausea, diarrhea, and bloating at higher doses. Due to mild antiplatelet and anticoagulant properties, resveratrol may potentiate the effects of warfarin, clopidogrel, and aspirin, increasing bleeding risk and warranting caution in patients on blood thinners. Resveratrol inhibits CYP3A4 and CYP2C9 enzymes, which may elevate plasma concentrations of drugs metabolized by these pathways, including statins, calcium channel blockers, and certain immunosuppressants. Safety data in pregnancy and lactation is insufficient, and use is not recommended in these populations or in individuals with hormone-sensitive conditions given weak estrogenic activity.